Anti-Rheumatic Rx

Patients with refractory gout and those with high burden of tophi have only few options when it comes to uric acid lowering agents. Many of these patients have coexisting chronic kidney disease (CKD…

The last day was jammed with important reports and research including the late breaking abstracts.    What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS,…

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty…

The ability to prevent rheumatoid arthritis (RA) in individuals at risk of developing this condition is a holy grail in rheumatology. There is a long-history of interest in this area dating back to…

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of…

There have been big advances in the treatment of axial spondyloarthritis (AxSpA) in the last decade. Biologic drugs that target TNF and IL-17 have become mainstay treatments in AxSpA if the disease…

The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of…

The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022.  These are their best studies for you to review and evaluate as part of your to-do…

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com and looks forward to highlight sessions in the next few days at ACR Convergence 2022. Study of 78 824 adults…

Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the…